The present specification relates to compounds of formula (I-X), (I) or their pharmaceutically acceptable salts, pharmaceutical compositions comprising them and their use as medicaments.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
C07D 239/90 - Oxygen atoms with acyclic radicals attached in position 2 or 3
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
The disclosure relates to a Cas9 protein comprising a polypeptide sequence having at least 95% identity, such as 97%, 98% or 99%, to SEQ ID NO: 1, wherein said polypeptide sequence comprises an amino acid modification at one or more positions relative to SEQ ID NO: 1: 37, 39, 46, 47, 54, 57, 59, 61, 94, 315, 501, 508, 556, 566, 911, 912, 978, 980, 1073, 1091, 1122, 1160, 1161, 1164, 1206, 1226 and/or 1229, CRISPR-Cas systems and methods for providing site-specific modification of a target sequence in a eukaryotic cell.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Pharmaceutical preparations for the treatment of antibodies; Vaccines
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Pharmaceutical preparations for the treatment of antibodies; Vaccines
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Pharmaceutical preparations for the treatment of antibodies; Vaccines
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Pharmaceutical preparations for the treatment of antibodies; Vaccines
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
9.
COMBINATION THERAPY COMPRISING DURVALUMAB AND CISPLATIN/GEMCITABINE FOR USE IN TREATING BLADDER CANCER
The disclosure relates to methods for treating patients with muscle-invasive bladder cancer using durvalumab and platinum-based chemotherapy. The present disclosure also relates to combination therapies comprising durvalumab and platinum-based chemotherapy for the treatment of patients with muscle invasive bladder cancer. The present disclosure further relates to the use of combination therapies comprising durvalumab and platinum-based chemotherapy for the manufacture of a medicament for treating patients with muscle invasive bladder cancer.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
10.
Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer
The disclosure relates to methods for treating patients with muscle-invasive bladder cancer using durvalumab and platinum-based chemotherapy. The present disclosure also relates to combination therapies comprising durvalumab and platinum-based chemotherapy for the treatment of patients with muscle invasive bladder cancer. The present disclosure further relates to the use of combination therapies comprising durvalumab and platinum-based chemotherapy for the manufacture of a medicament for treating patients with muscle invasive bladder cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 39/00 - Medicinal preparations containing antigens or antibodies
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for use in oncology; Pharmaceutical preparations and substances for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, neurological, gastrointestinal and immune systems; Pharmaceutical preparations and substances for the treatment of infection and inflammation; Pharmaceutical preparations and substances for the treatment of hematological, autoimmune, and immune-mediated diseases and disorders; Pharmaceutical preparations and substances, namely, pharmaceutical antibodies for neutralizing viruses; vaccines for humans
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for use in oncology; Pharmaceutical preparations and substances for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, neurological, gastrointestinal and immune systems; Pharmaceutical preparations and substances for the treatment of infection and inflammation; Pharmaceutical preparations and substances for the treatment of hematological, autoimmune, and immune-mediated diseases and disorders; Pharmaceutical preparations and substances, namely, pharmaceutical antibodies for neutralizing viruses; vaccines for humans
19.
ANTI-PCRV AND PSL BISPECIFIC ANTIBODIES FOR TREATMENT OF BRONCHIECTASIS
A pharmaceutical composition comprising: (a) one or more of a first pellet comprising i. a first core, and ii. a first coating on the first core, wherein the first coating comprises a mineralocorticoid receptor (MR) modulator and a first binder; and (b) one or more of a second pellet comprising i. a second core, and ii. a second coating on the second core, wherein the second coating comprises an SGLT2 inhibitor, wherein the SGLT2 inhibitor is about 5% to about 20% by weight of the second pellet, wherein the composition comprises about 20% to about 50% by weight of the mineralocorticoid receptor (MR) modulator; and about 1% to about 10% by weight of the SGLT2 inhibitor. Said compositions for use in the treatment of chronic kidney disease or heart failure.
Therapeutic combinations of capivasertib and venetoclax are described. The combinations can be useful in the treatment of B-cell malignancies. In some embodiments, reduced dosing (e.g., reduced frequency and/or reduced amount) of venetoclax can mitigate or abrogate effects such as body weight loss that may be experienced with an initial dosage regime.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
The present specification concerns therapeutic approaches for the treatment of wounds, especially chronic wounds experienced by patients whose ability to heal skin is impaired (e.g. diabetes sufferers). The therapies are based on the use of resorbable glass beads (for example calcium phosphate glass microspheres) alone or in combination with an 11β-hydroxysteroid dehydrogenase type I (11β-HSD1) inhibitor such as (S)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid (AZD4017, compound (I) below).
A61L 27/58 - Materials at least partially resorbable by the body
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 5/46 - Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Solid-state forms of N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide; corresponding pharmaceutical compositions; uses to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits; and methods of preparation.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in medicine.
The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in medicine.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine.
The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
36.
6-AMINOPURINE DERIVATIVES USEFUL AS POLQ INHIBITORS
abb, X, Y, R1, R2, Q1, Q2, and Q3have any of the meanings defined herein, together with compositions containing them and their use in therapy. The compounds are inhibitors of the polymerase, DNA polymerase theta (Polθ or POLQ), and are thereby particularly useful in the treatment of cancer.
C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present invention relates to the treatment of melanoma in a patient, where the method includes administering to a patient who has or is suspected of having melanoma a therapeutically effective amount of tebentafusp; and a therapeutically effective amount of an immune checkpoint inhibitor. In particular, patients may have metastatic melanoma that is refractory to treatment with an anti-PD(L)1 inhibitor in the metastatic setting or where the patient's melanoma is relapsed following treatment with an anti-PD(L)1 inhibitor.
abb, X, Y, R1, R2, Q1, Q2, and Q3 have any of the meanings defined herein, together with compositions containing them and their use in therapy. The compounds are inhibitors of the polymerase, DNA polymerase theta (Polθ or POLQ), and are thereby particularly useful in the treatment of cancer.
The present disclosure provides methods for treating a disease associated with apolipoprotein L1 (APOL1) comprising administering an APOL1 oligonucleotide defined herein. The present disclosure also provides unit dosages comprising the APOL1 oligonucleotide.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A spin chamber for use in an inhaler includes a primary recess to receive air to mix with contents of a capsule. The primary recess has a curved wall. The spin chamber includes a secondary recess to hold a capsule. The secondary recess is located within a bottom surface of the primary recess. The spin chamber includes at least one curved inlet channel to allow air to travel therethrough. The curved inlet channel includes a tangential section and a funnel section. At least a portion of the tangential section is substantially tangential to the curved wall of the primary recess and is connected to an air inlet on an exterior surface of the spin chamber. The funnel section curves toward the primary recess and is connected to an entry point to allow air to enter therethrough into the primary recess.
The present specification relates to AZD9833 for use in the treatment of cancer and methods of treatment of cancer involving administration of AZD9833 wherein, in each case, the AZD9833 is administered orally once daily at a dose between 25 mg and 450 mg. AZD9833 may be administered alone or its use may be in combination with an additional anti-cancer agent such as a CDK inhibitor, everolimus or an AKT inhibitor.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A method of lowering LDL-C levels, reducing cardiovascular risk and/or treatment of a cardiovascular disease, comprising administering to a subject in need thereof, a first amount of AZD0780 or a pharmaceutically acceptable salt thereof and a second amount of ezetimibe or a pharmaceutically acceptable salt thereof, wherein the first amount and the second amount together comprise a therapeutically effective amount.
A spin chamber (103) for use in an inhaler (200) includes a primary recess (104) to receive air to mix with contents of a capsule. The primary recess has a curved wall (401). The spin chamber includes a secondary recess (105) to hold a capsule (213). The secondary recess is located within a bottom surface of the primary recess. The spin chamber includes at least one curved inlet channel (301) to allow air to travel therethrough. The curved inlet channel includes a tangential section (402) and a funnel section (403). At least a portion of the tangential section is substantially tangential to the curved wall of the primary recess and is connected to an air inlet (302) on an exterior surface of the spin chamber. The funnel section curves toward the primary recess and is connected to an entry point (405) to allow air to enter therethrough into the primary recess.
An inhaler includes a main body and a drawer to open out of and close into the main body between an open position and a closed position. The drawer includes a spin chamber having a primary recess to receive air to mix with contents of a capsule and a secondary recess to hold the capsule. When the drawer is in the open position, the secondary recess is exposed to receive a new capsule therein or to withdraw a used capsule therefrom. When the drawer is in the closed position, the capsule is enclosed within the inhaler. The inhaler includes a perforating means to perforate the capsule. The perforating means moves away from a resting position toward a perforating position as the drawer moves into the main body. When set at the perforating position, the perforating means is positioned within the secondary recess to perforate the capsule.
An inhaler includes a main body having an inhalation chimney and a mouthpiece. The inhalation chimney includes a bottom surface. The inhaler includes a drawer for receiving a capsule. The drawer includes a top surface. The drawer opens out of and closes into the main body. The drawer moves into the main body from an open position to a closed position or out of the main body from the closed position to the open position, such that the movement of the drawer causes the inhalation chimney to move with respect to the mouthpiece. When the drawer is in the closed position, the top surface of the drawer and the bottom surface of the inhalation chimney are held together.
The present provides a method of treating ovarian cancer, breast cancer, gastrointestinal cancer, lung cancer, cancer of the brain or prostate cancer in a subject in need thereof, comprising administering to the subject a first amount of a selective PARP1 inhibitor or a pharmaceutically acceptable salt thereof, and a second amount of an ATR inhibitor or a pharmaceutically acceptable salt thereof. Also disclosed are compositions and kits comprising a PARP inhibitor and ATR inhibitor.
An inhaler (100, 200, 400) includes a main body (101) having an inhalation chimney (210) and a mouthpiece (211). The inhalation chimney includes a bottom surface. The inhaler includes a drawer (102) for receiving a capsule (213). The drawer includes a top surface. The drawer opens out of and closes into the main body. The drawer moves into the main body from an open position to a closed position or out of the main body from the closed position to the open position, such that the movement of the drawer causes the inhalation chimney to move with respect to the mouthpiece. When the drawer is in the closed position, the top surface of the drawer and the bottom surface of the inhalation chimney are held together.
An inhaler (100, 200, 300, 400) includes a main body (101) and a drawer (102) to open out of and close into the main body between an open position and a closed position. The drawer includes a spin chamber (103) having a primary recess (104) to receive air to mix with contents of a capsule (213) and a secondary recess (105) to hold the capsule. When the drawer is in the open position, the secondary recess is exposed to receive a new capsule therein or to withdraw a used capsule therefrom. When the drawer is in the closed position, the capsule is enclosed within the inhaler. The inhaler includes a perforating means (204) to perforate the capsule. The perforating means moves away from a resting position toward a perforating position as the drawer moves into the main body. When set at the perforating position, the perforating means is positioned within the secondary recess to perforate the capsule.
The specification relates to conjugates comprising one or more Dcand pharmaceutically acceptable salts thereof. The specification also relates the use of the conjugates for the treatment of diseases such as cancer, and intermediates useful for the synthesis of the conjugates.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07D 471/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed systems contains four or more hetero rings
The disclosure generally relates to binding proteins that comprise antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site. The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure provides a method of treating asthma in a subject at risk of asthma exacerbation, and a method of as-needed treatment or prevention of bronchoconstriction in a subject, and/or prevention of exacerbation in a subject with asthma, comprising administering as needed to the subject a composition comprising therapeutically effective amounts of albuterol and budesonide, wherein the composition is administered via a metered dose inhaler, wherein the method reduces risk of severe asthma exacerbation by at least about 15% as compared to administration of a composition comprising a same dose of albuterol alone, as measured by time-to-first severe asthma exacerbation. Also provided is a pharmaceutical composition comprising: albuterol and budesonide in the form of particles; a suspension medium comprising a hydrofluoroolefins (HFO) propellant and/or a hydrofluorocarbon propellant (HFC), and a plurality of respirable suspending particles, wherein the particles of albuterol and budesonide associate with the plurality of respirable suspending particles.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
The present disclosure relates to methods of increasing time to second progression or death and time to first subsequent chemotherapy in subjects having advanced breast cancer using therapeutic combinations of capivasertib and fulvestrant.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
The present disclosure provides compositions comprising anti-CTLA-4 antibodies and related methods for treating cancer and other disorders responsive to anti-CTLA-4 antagonism.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
60.
COMPOSITIONS AND METHODS FOR DELIVERING A MACROMOLECULE TO A CELL 2
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Antibodies for medical purposes; Vaccines
The disclosure relates to methods and compositions for the treatment of systemic lupous erythematous (SLE). Specifically, the disclosure relates to methods comprising administering to a subject a type I IFN receptor inhibitor.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
63.
SOLID FORMS OF HETEROCYCLYLAMIDES AS IRAK4 INHIBITORS
The present specification relates to novel physical forms of a indazole-5-carboxamide derivative, as well as solvate and salt forms of the same compound. A process for the preparation of the compound and uses of the new physical forms are also provided.
The present disclosure provides meglumine salts of CX3CR1 modulators, polymorphs and pharmaceutical compositions thereof. Also disclosed are methods of treatment using the meglumine salts of CX3CR1 modulators, polymorphs and pharmaceutical compositions thereof and methods of making salt compounds of CX3CR1 modulators and polymorphs thereof.
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
65.
EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCER
The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the adjuvant treatment after tumour resection of patients with epidermal growth factor receptor-mutation-positive (EGFRm) non-small cell lung cancer (NSCLC).
The present disclosure provides thio-substituted 1,3,5-triazine CX3CR1 modulators, pharmaceutical compositions thereof and uses thereof for the treatment of cardiovascular disease.
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 251/18 - Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present disclosure provides a method of treating a subject having or at risk of developing a liver disease, the method comprising administering to the subject a composition comprising about 10 mg to about 90 mg of an inhibitor of patatin-like phospholipase domain-containing protein 3 (PNPLA3) expression and a pharmaceutically acceptable carrier and/or excipient, wherein, the inhibitor of PNPLA3 expression comprises an antisense oligonucleotide comprising a nucleobase sequence complementary to a region of a nucleic acid encoding PNPLA3. In some embodiments, the methods and dosage forms are useful for treating, preventing, or ameliorating a disease associated with PNPLA3 in a subject having an I148M mutation.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
An example embodiment may involve obtaining, by a computing system, an observation of demographic values of an individual, vital sign values of the individual, and blood test values of the individual: applying, by the computing system, a machine learning model to the observation, wherein the machine learning model was trained with a training data set, wherein the training data set contained observations of corresponding demographic values, vital sign values, blood test values, and either urine albumin-to-creatinine ratio (UACR) values or urine protein-to-creatinine ratio (UPR) values for a plurality of individuals, and wherein the machine learning model is configured to provide predictions of whether further observations are indicative of undiagnosed albuminuria or proteinuria; and providing, by the computing system, a prediction of whether the individual exhibits undiagnosed albuminuria or proteinuria based on the observation.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase:
Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase:
Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase:
wherein
R1 is —NHR1a;
R1a is —H or —C(O)CH(R1b)NHR1c; and
R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d and R1c is —H; or
R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and
R1d is H or —CH3.
C07D 473/16 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
A compound with the Formula (I): A-B-C (I) or a pharmaceutically acceptable salt and tautomeric forms or stereoisomers thereof, wherein A is of one of the following formulae: (A1a), (A2a), (A2b), (A3a) and (A3b); B is of formula: (B-1); and C is of formula: (C-1a), (C-1b), (C-1c) or (C-1d).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A compound with the Formula (I): A-B-C (I) or a pharmaceutically acceptable salt and tautomeric forms or stereoisomers thereof, wherein A is of one of the following formulae: (A1a), (A2a), (A2b), (A3a) and (A3b); B is of formula: (B-1); and C is of formula: (C-1a) or (C-1b).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61P 9/00 - Drugs for disorders of the cardiovascular system
A compound with the Formula (I): A-B-C (I) or a pharmaceutically acceptable salt and tautomeric forms or stereoisomers thereof, wherein A is of one of the following formulae: (A1a), (A2a), (A2b), (A3a), (A3b), and (A4); B is of formula: (B-1); and C is of formula: (C-1a).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
80.
PROCESSES AND COMPOUNDS FOR THE PREPARATION OF TOPOISOMERASE I INHIBITOR LINKER-PAYLOADS
This specification relates to processes and intermediate compounds involved in the preparation of Topoisomerase I inhibitor (TOPO1i) linker-payloads suitable for the synthesis of antibody conjugates.
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
C07D 495/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances.
82.
AZD1390, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN COMBINATION WITH RADIATION FOR USE IN A METHOD OF TREATMENT OF A CENTRAL NERVOUS SYSTEM (CNS) TUMOUR
AZD1390, or a pharmaceutically acceptable salt thereof, for use in a method of treatment of a CNS tumour, wherein said treatment comprises the separate, sequential or simultaneous administration of i) a total daily dose of about 200 mg of said AZD1390, optionally in the form of a pharmaceutically acceptable salt thereof, and ii) radiation therapy, to said subject.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
Disclosed are compounds of formula (Ib) or (Vc), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ib) or (Vc) and methods of using the same for treating cancer, respiratory inflammatory disease, and inhibiting arginase:
Disclosed are compounds of formula (Ib) or (Vc), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ib) or (Vc) and methods of using the same for treating cancer, respiratory inflammatory disease, and inhibiting arginase:
Disclosed are compounds of formula (Ib) or (Vc), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ib) or (Vc) and methods of using the same for treating cancer, respiratory inflammatory disease, and inhibiting arginase:
wherein
R1 is —H or —C(O)CH(R1a)NHR1b; and
R1a is selected from —H, —(C1-C4) alkyl and CH2OR1c;
R1b is —H; or alternatively, R1a and R1b, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and
R1c is H or —CH3.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 13/00 - Drugs for disorders of the urinary system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Provided are lipid conjugated oligonucleotides that allow for delivery of the oligonucleotides to specific tissues in the body. The lipid on the conjugated oligonucleotide comprises an acyl group having a free terminal carboxylic acid group. Also provided are methods for synthesizing lipid conjugated oligonucleotides having with a lipid comprising an acyl group having a free terminal carboxylic acid group, along with methods for delivering the lipid conjugated oligonucleotides and methods for using the lipid conjugated oligonucleotides for treating disease.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
The present disclosure provides a method of treating chronic obstructive pulmonary disease (COPD) in a subject with a triple combination therapy. The method comprises administering to the subject twice daily a therapeutically effective dose of a composition comprising budesonide, glycopyrronium and formoterol fumarate, wherein the dose is administered to the subject via a metered dose inhaler, and the subject is at an elevated risk of a COPD exacerbation event and cardiovascular disease.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
